Curing cancer has a name

GUSTAVE ROUSSY
CANCER CAMPUS
GRAND PARIS

FOREWORD



"Cancer is this century's greatest challenge, affecting every one of us. Since the 1990s, the number of new cases has doubled. Fortunately, thanks to the efforts of the world's leading cancer centres and the support of committed donors, the cure rate has increased from 50% to 66%. Within the last thirty years, we have made more progress than in the entire previous century. Now is the time to step up our fight against this disease, which affects a growing number of lives. We firmly believe that we will be able to cure 80% of cancers by 2040. With the support of French and European public authorities and our partners, I will devote all my energy to this fight, backed by the formidable teams at Gustave Roussy. However, this task demands considerable resources. Your commitment will be decisive in winning this intergenerational challenge. It calls for extraordinary philanthropic support, and I need you to secure it. Together, we can do this, and it's thanks to you that we will succeed!"

Prof. Fabrice Barlesi

CEO of Gustave Roussy

CHOOSE THE LEADING CANCER INSTITUTION
in France and Europe

Born from the vision of Professor Gustave Roussy, a pioneer in multidisciplinary cancer care, Gustave Roussy is the leading cancer centre in France and Europe. **A private, not-for-profit institution, it ranks fourth in the world in the *Newsweek* ranking of the best specialised oncology hospitals in 2025, and is also among the most prestigious institutions according to *Le Point* magazine.**

Le Point — WORLD'S BEST SPECIALIZED HOSPITALS 2025 — Newsweek — statista

A leading centre for the treatment of cancers in adults and children, Gustave Roussy exemplifies excellence in medicine, science and academia. The institution has chosen an integrated model, combining care, research and education to deliver personalised medicine tailored to the specific needs of each patient.

Located in Villejuif, Gustave Roussy is now at the heart of the Paris-Saclay Cancer Cluster, a true European driver of innovation in oncology. This exceptional site brings together three complementary entities: a healthcare campus integrating all medical disciplines, a rapidly expanding research campus with a new 33,000 m² research centre set to double the number of research teams by 2028, and an industrial campus dedicated to start-ups and biotechs, with 100,000 m² dedicated to innovation.

In just a few years, Gustave Roussy has been able to create a unique ecosystem, bringing together world-renowned researchers, clinicians, major industrialists and investors. This interconnected framework, designed to foster synergies between fundamental research, industrial innovation and high-tech care, embodies a new way of thinking and shaping the medicine of tomorrow.

OUR CREDENTIALS

100 years of innovation and success

OUR POSITION

An integrated, multidisciplinary model, considered the most advanced in France and Europe

OUR REQUIREMENT

The excellence of research and care "made in France"

OUR AMBITION

To cure 80% of cancers by 2040

The strength of a collective and its five activities

Gustave Roussy operates through five distinct but interconnected entities, each playing a crucial role in the group's strength.

GUSTAVE ROUSSY
CANCER CAMPUS GRAND PARIS

GUSTAVE ROUSSY – CANCER CENTER

The main entity serves as the operational core of the institution, delivering multidisciplinary, innovative and personalised care to patients while developing cutting-edge clinical trials supported by philanthropic commitment.

GUSTAVE ROUSSY
CANCER CAMPUS GRAND PARIS
FONDATION

GUSTAVE ROUSSY – FOUNDATION

The Gustave Roussy Foundation supports the development of translational research, working closely with scientific and medical teams. It supports scientific and technological innovation programmes, plays a key role in funding large-scale projects through donor generosity, and contributes to creating chairs of excellence, attracting new talent.

GUSTAVE ROUSSY
CANCER CAMPUS GRAND PARIS
ÉDUCATION

GUSTAVE ROUSSY – EDUCATION

In partnership with Paris-Saclay University, Gustave Roussy Education leads initial and continuing education in healthcare and science. Each year, Gustave Roussy Education trains thousands of students, interns, researchers and healthcare professionals, thereby contributing to the dissemination of knowledge and the evolution of oncology practices.

GUSTAVE ROUSSY
CANCER CAMPUS GRAND PARIS
TRANSFERT

GUSTAVE ROUSSY – TRANSFER

Dedicated to maximising research value and promoting innovation, it helps transform scientific discoveries into practical applications that benefit patients through industry partnerships, the creation of start-ups and acceleration schemes.

GUSTAVE ROUSSY
CANCER CAMPUS GRAND PARIS
INTERNATIONAL

GUSTAVE ROUSSY – INTERNATIONAL

The international entity ensures the spread of Gustave Roussy's expertise on a global scale. It develops partnerships with leading institutions, coordinates the largest network of alumni in Europe (2,000 members from 25 different nationalities) and actively participates in collaborative projects around the world.

Our key figures

4,000
EMPLOYEES

€600
MILLION OVERALL BUDGET

138,000
PATIENT STAYS (FULL HOSPITALISATION, DAY CARE, CHEMOTHERAPY AND RADIOTHERAPY SESSIONS)

600 BEDS AND SPACES
(ACROSS THE VILLEJUIF AND CHEVILLY-LARUE SITES)

280,000 MEDICAL CONSULTATIONS
(INCLUDING 17,000 IN PAEDIATRICS)

52,000
PATIENTS UNDER OUR CARE (INCLUDING 2,700 IN PAEDIATRICS)

24,000
NEW PATIENTS

An integrated and innovative COMPREHENSIVE RESPONSE

Gustave Roussy implements a comprehensive strategy spanning the entire care pathway that draws on major innovations to deliver optimal care tailored to the specific needs of each cancer patient.

INTERCEPTION GUSTAVE ROUSSY Le programme de prévention personnalisée des cancers

1. Strengthening prevention

is a major priority, driven in particular by the Interception programme, launched in 2021. This innovative system seeks to detect cancers early, targeting people at increased risk based on a detailed understanding of biological mechanisms and risk factors.

INSTADiag FOIE - PANCRÉAS BY GUSTAVE ROUSSY

2. Speeding up diagnosis

is crucial to improving the chances of recovery. To this end, Gustave Roussy has set up the InstaDiag pathways, which are rapid and personalised diagnosis channels, organised according to the types of cancer concerned: breast, thyroid, liver, pancreas, gynaecological cancers, lung and, very soon, sarcomas. These pathways eliminate lengthy waiting periods and multiple referrals by offering direct access to examinations and specialist consultations at the first signs.

FRESH

3. Personalising treatments

is at the heart of the therapeutic strategy. Gustave Roussy does this by using cutting-edge tools, including FRESH liquid biopsy, which allows real-time monitoring of tumour evolution using a simple blood test, and IHU Prism, which combines molecular analysis with computer modelling to optimise therapies. Additionally, innovative artificial intelligence projects such as MosAIc and PortrAIt are pioneering even more precise and responsive precision medicine.

4. Therapeutic innovation

remains our unwavering goal. Gustave Roussy develops advanced therapeutic approaches, particularly in the field of radioligands, which directly target cancer cells through targeted internal radiotherapy, as well as cell therapies, including immunotherapy. FLASH radiotherapy, a revolutionary technique offering faster and less toxic treatment, is in clinical development at the site. At the same time, Gustave Roussy is maintaining its position as a world leader in the field of antibody conjugates, targeted treatments combining antibodies and cytotoxic agents.

5. Providing long-term support

to patients after treatment is an essential component of care. Gustave Roussy offers pragmatic trials to assess the real impact of care on quality of life, and uses the Resilience platform, a personalised post-cancer support system. Our Transition Days also provide a dedicated space to prepare individuals for their return to life after cancer by addressing medical, psychological and social aspects to support their reintegration and overall well-being.

INNOVATING
for better care

Recent months have seen major innovations at Gustave Roussy. From contact radiotherapy to 3D printing in dentistry, new advances are improving patient care every day.

Gustave Roussy acquired the Papillon+ system last year. This technique, used to treat certain rectal and skin cancers, eliminates the need for major surgery. For rectal tumours under 3 cm, it avoids ablation in 97% of cases, compared to 63% with chemotherapy alone. A phase III clinical trial, called TRESOR and coordinated by the Institute, is now exploring its efficacy in tumours up to 6 cm. Gustave Roussy has thus become the fourth centre in France to offer this rapid, effective technology reimbursed by the French health insurance system.



In imaging, the arrival of the latest-generation 3 Tesla MRI marks a significant step forward. Dedicated to radiotherapy and brachytherapy, it allows examinations to be carried out in the same position as that adopted during treatment, thus optimising therapeutic precision. It is also suitable for the care of children under general anaesthesia, and supports the development of personalised treatments, particularly in neurology.

Another notable innovation is the Veriton-CT 400 gamma camera, a latest-generation SPECT/CT digital system. Its 12 mobile detectors allow 3D imaging of the whole body, with superior accuracy and reduced radiotracer doses. It improves theranostic protocols with Lutetium-177 and facilitates paediatric management through faster and less invasive examinations.

Finally, the odontology and maxillofacial prosthesis unit has integrated a complete 3D scanning, design and printing chain. With this technology, we can create digital twins of patients, streamlining the creation of custom surgical guides, anatomical models and dental prostheses. Used notably in the treatment of ENT cancers, it enhances the precision of post-surgical dental rehabilitation, shortens treatment times and contributes to a better quality of life.

GLOBAL RESEARCH with societal impact

Gustave Roussy reaches new milestones each year. Through structured projects, cutting-edge technologies and an integrated approach to care, the Institute reaffirms its mission: to transform every scientific breakthrough into a clinical reality, bringing each one closer to patients

Our key figures

RESEARCH

- 1,400 researchers and research staff
- 1,200 scientific publications
- 213 international publications in journals with *Impact Factors* between 10 and 30 (excluding conferences)
- 43 exploratory and translational research teams
- 11 technology platforms
- 9 university-hospital research (Recherche-Hospitalo-Universitaire, RHU) projects
- 3 PIA cohorts (CANTO, E3N, Coblance)
- Artificial intelligence: a database of 400,000 patients (1 division, 4 CESP teams and 3+1 IHU teams)

CLINICAL RESEARCH

- 13 clinical committees + 1 clinical research department
- 1 Therapeutic Innovation and Early Trials Department
- 1 new clinical research platform
- 368 scientific publications
- 6,153 patients enrolled in clinical studies – **leading centre in France and Europe in terms of the number of patients enrolled in clinical studies**
- 586 active clinical trials

AN INTERNATIONAL scientific reputation

Gustave Roussy is France's leading institution in terms of scientific publications in oncology, with by far the largest concentration in France of the world's most cited researchers (16) and the highest number of patients treated, particularly in the field of clinical trials.

Many of the scientific discoveries made at Gustave Roussy have become standard treatments for cancer worldwide (discoveries of LAG-3, JAK2 and TET2 mutations, the role of the microbiome, etc.)


FABRICE BARLESI


FABRICE ANDRÉ


BENJAMIN BESSE


CAROLINE ROBERT


KARIM FIZAZI


LAURENCE ZITVOGEL


GUIDO KROEMER


OLIVIER KEPP


FLORENT GINHOUX


ANTOINE ITALIANO


DAVID PLANCHARD


LAURENCE ALBIGES


AURÉLIEN MARABELLE


JEAN-CHARLES SORIA


ÉRIC VIVIER


CHARLES-ANTOINE DUTERTRE

ACCELERATING research, shaping excellence

"The first three immuno-oncology chairs have been created, with the aim of accelerating the development of new treatments that could transform patient care over the next five to ten years. They are held by Alexandre Detappe (specialising in nanotechnologies applied to immunotherapy), Eric Vivier (global expert in NK cell immunology) and Florent Ginhoux (laboratory director at the U1015 unit –Tumour Immunology and Immunotherapies)."

Anne Paoletti,
Director of the Gustave Roussy Foundation

In 2023, the Gustave Roussy Foundation restructured its organisation to drive new momentum to serve patients.

It has adopted new articles of association and is fully committed to an ambitious strategy: supporting high-impact research and accelerating innovation in oncology at Gustave Roussy as part of a unique ecosystem that draws together Gustave Roussy researchers and clinicians, as well as companies from the Paris-Saclay Cancer Cluster, to transform scientific discoveries into tomorrow's treatments. In 2024, the Foundation implemented its first scientific research programmes.

Chairs of Excellence: attracting new talent

As a symbol of this transformation, the Chairs of Excellence programme seeks to attract the best talent in oncology. Funded through donor generosity, it selects researchers recognised by an independent jury based on a single criterion: scientific excellence.

Emerging programmes: exploring disruptive new approaches

In February 2024, the Foundation and the Institute launched a joint call for two-year emerging programme proposals. These innovative and ambitious programmes for disruptive scientific and/or technological breakthroughs explore and seek to consolidate new perspectives in oncology and produce proof of concept to justify the further development of a larger-scale programme. Five winning projects were selected in July 2024 out of 23 submissions, three of which will be funded by the Foundation. Inserm Research Fellow Laurie Menger's project aims to enhance innovative CAR-T cell therapies. That of Kristine Schauer, Research Director at the CNRS, studies resistance mechanisms to antibody-drug conjugates (ADCs). The third, led by Filippo Dal'Ollio, clinician-researcher at Gustave Roussy, and Yegor Vassetzky, Research Director at the CNRS, focuses on the phenomenon of sarcopenia in head and neck cancers.

The equipment programme: ensuring a state-of-the-art technological environment to accelerate research

The Foundation has funded a new state-of-the-art equipment programme to the tune of €1 million to strengthen its technological platforms and make Gustave Roussy's research teams more competitive.

7 PRIORITY RESEARCH AREAS

- DNA REPAIR & GENOME STABILITY
- PAEDIATRIC CANCERS
- DATA SCIENCE AND ARTIFICIAL INTELLIGENCE
- NEW THERAPIES
- RADIOTHERAPY
- METABOLISM AND CANCER
- HAEMATOLOGY

An environment of excellence for research

- → 1 technology equipment programme
- → 3 Chairs of Excellence
- → 5 emerging programmes
- → 5 young team supports
- → 6 pragmatic trials
- → 9 medical-scientific programmes
- → 95 projects supported
- → €6.9 million in research grants (including €4 million in donations allocated by the donor).

A NETWORK
of international partnerships



Gustave Roussy pursues an active international strategy to promote its model of care centred on excellence, innovation and universal access. By drawing on institutional and hospital partnerships, the Institute extends its mission of care, training and knowledge transfer well beyond its borders.

Driven by its subsidiary Gustave Roussy International, this policy is reflected in:

- short-term and multi-year hospital projects (support, audits, co-development) in several partner countries
- cooperation agreements to structure networks of partner and satellite centres
- training and skills development programmes for international healthcare professionals.

Gustave Roussy Alumni: an engaged community

GUSTAVE ROUSSY ALUMNI

Gustave Roussy brings together an international alumni community comprising former trainees, residents, researchers and professionals trained at the Institute. These alumni also serve as ambassadors for excellence in oncology, both in France and abroad.

- France's leading oncology alumni network
- More than 2,000 members, former Gustave Roussy doctors
- 25 nationalities represented

Sharing Gustave Roussy's expertise in French overseas territories

Since 2019, Gustave Roussy has organised multidisciplinary team meetings (MDTs) for overseas patients, working closely with hospitals and clinics in the territories concerned.

In 2024, more than 2,000 overseas patient cases were discussed, demonstrating the solidity and sustainability of this partnership.

These regular remote MDTs include:

- The French Polynesian hospital in Papeete
- University hospitals in Martinique, Guadeloupe and Réunion

This organisation provides specialist expertise, reduces medical evacuations to mainland France and shortens treatment times. Patients thus benefit from faster access to accurate diagnosis and appropriate treatments, either locally or at a specialist centre in mainland France.

PASSING ON EXCELLENCE in oncology

GUSTAVE ROUSSY
CANCER CAMPUS
GRAND PARIS
ÉDUCATION

In partnership with Paris-Saclay University, Gustave Roussy Education is the Institute's dedicated structure for initial, continuing and international training. It reflects Gustave Roussy's commitment to sharing its oncology expertise with all generations of healthcare professionals, both in France and abroad.

Through an innovative educational provision that combines face-to-face training, remote training and simulation, Gustave Roussy Education supports healthcare providers, researchers, residents and students in acquiring high-level skills aligned with the latest scientific and clinical advances.

TRAINING PROVISION

- → 23 university degrees
- → 14 master classes

NUMBER OF STUDENTS

- → More than 10,000 participants registered on the digital teaching platform
- → More than 4,300 students trained
- → 2,600 new registrants on the digital teaching platform
- → 1,400 seminar participants
- → 730 enrolled in university degrees
- → 223 doctoral students enrolled in the doctoral school
- → 110 engineering students specialising in healthcare professions at the Institute of Advanced Biomedical Training (Institut de Formation Supérieure BioMédicale, IFSBM)
- → 30 students enrolled in the Oncology 2 Master's

NUMBER OF TEACHERS

- → 41 university faculty members
- → 230 teaching practitioners

SHOWCASING medical innovation

GUSTAVE ROUSSY
CANCER CAMPUS
GRAND PARIS
TRANSFERT

At the intersection of research, clinical practice and entrepreneurship, Gustave Roussy Transfer is the embodiment of Gustave Roussy's mission: to develop tomorrow's therapeutic innovations to deliver increasingly personalised and effective medicine.

From support for intellectual property protection to the creation of start-ups, partnership negotiations and the optimisation of clinical data, Gustave Roussy Transfer plays a strategic role in promoting the Institute's scientific excellence both in France and abroad.

Working directly with the Paris-Saclay Cancer Cluster, this entity actively contributes to the structuring of a unique ecosystem capable of nurturing and growing the most innovative projects in oncology.

Our key figures

110
PATENT FAMILIES,
INCLUDING 70 MANAGED DIRECTLY BY GUSTAVE ROUSSY

87
TRANSLATIONAL COLLABORATION CONTRACTS
SIGNED, INCLUDING 58 WITH EXTERNAL FUNDING

19 COMPANIES CREATED, INCLUDING 10 NEW ONES SINCE 2021

2 COMPANIES
CREATED IN 2024: SPOTLIGHT MEDICAL AND THERASONIC

1 OFFICE
IN BOSTON

2 NEW PROJECTS
SUPPORTED WITH FUNDING FROM THE PARTNERSHIP WITH SOFINNOVA PARTNERS

CURING 80% OF CANCERS with your help

Ours is an ambitious goal: to cure the majority of adult and childhood cancers within the next fifteen years! By joining our circle of leading philanthropists and offering your generous support, you can help us to cure another 15% of cancers within fifteen years, bringing the cancer cure rate up to 80%!

This requires better prevention to detect cancer earlier and breakthrough inductive research to cure the 20% of cancers that remain incurable. Several ambitious projects are therefore underway at Gustave Roussy to give hope to 100% of patients.

Building Europe's largest cancer campus

Gustave Roussy's scientific vision requires scaling up to draw this new talent and gather the best expertise to accelerate victories against cancer for the benefit of patients. Europe's largest cancer campus is being built with and around Gustave Roussy.

The Paris-Saclay Cancer Cluster (PSCC), co-founded by Gustave Roussy to accelerate the development of new cancer treatments, medical devices and diagnostic solutions in France, is already on campus. Biotechnology companies are setting up in new buildings near the Institute.

By 2028, the construction of a new 33,000 m² Gustave Roussy research centre, costing €190 million (one-third of which is funded by sponsorship), will double the number of research teams and provide them with a 3.0 environment for agile and collaborative research excellence.

In 2029, opposite the new Villejuif-Gustave Roussy metro station opened in January 2025, there will be a new Gustave Roussy building for cancer interception and rapid diagnosis.

Finally, in 2027, a new Gustave Roussy extension dedicated to education and support functions will be completed alongside the A6 motorway.

Doubling our research capacity by attracting internationally renowned researchers

In 2020, Gustave Roussy had just 30 research teams; 12 young researchers of international standing were recruited between 2021 and 2024, suggesting that the target of 30 new hires over 10 years is realistic. This represents 1,200 to 1,400 people dedicated to research at Gustave Roussy, including 200 to 300 independent international researchers.

Advancing treatments through new technologies and artificial intelligence

AI TOOLS

Gustave Roussy professionals participate in international collaborations and initiatives, such as the partnership with Owkin, a French health AI unicorn, to develop AI tools for digital pathology, showcasing their expertise in integrating advanced technologies into medical practice (*French Healthcare*).

AVATARS AND ORGANOIDS

Avatars and organoids represent a transformative approach to oncology, enabling personalised and precise treatment strategies. With their faithful reproduction of a patient's tumour biology, these models are powerful tools for understanding cancer and developing effective therapies.

INNOVATIVE MEDICINES AND DEVICES

The combination of state-of-the-art facilities, interdisciplinary collaborations, commitment to personalised and patient-centred care, robust clinical trial programmes and strong industrial partnerships positions Gustave Roussy as a leading institution in the development of new medicines and medical devices in oncology.

DIGITAL APPLICATIONS INTEGRATING PATIENT FEEDBACK

Gustave Roussy's research strategy includes integrating patient experiences and outcomes through digital monitoring solutions such as Resilience, co-created by Gustave Roussy. By integrating these monitoring elements into its research strategy, Gustave Roussy is changing the traditional paradigms of oncology and accelerating the discovery of innovative treatments based on patient experience.

"Gustave Roussy's objective is to host 45 research teams by 2025 and 60 by 2030, including experimental and theoretical teams. Recruitment is focused on highly promising young scientists or clinician-researchers capable of leading new research teams. The number one challenge for a research centre is therefore to attract new talent capable of making high-impact discoveries. We are aiming to recruit 25 global leaders in their field by 2030."

Prof. Fabrice André
Director of Research at Gustave Roussy

Cure all cancers in the 21st century? What if you could be part of this revolution?

As leaders in our fields, we have a duty to support Europe's oncology champion! Gustave Roussy draws on major breakthroughs, intensive collaboration, world-class talent and a scientific vision capable of transforming the lives of millions of patients. All that is needed are the means to achieve it!

By pooling our strengths and networks, leveraging the best expertise and strong philanthropic momentum, we will succeed in curing all cancers in the 21st century!

Sébastien Bazin,
CEO of ACCOR Group and President of the Gustave Roussy Foundation

YOUR KEY CONTACTS

PERRINE DE LONGEVIALLE
Brand and Philanthropy Director
perrine.de-longevialle@gustaveroussy.fr

GAËLLE LE ROUX
Head of Resource Development
gaelle.le-roux@gustaveroussy.fr

ANNE-SOPHIE DE BOISSARD
Head of Campaigns and International Fundraising
anne-sophie.de-boissard@gustaveroussy.fr

Giving with confidence

Financial transparency, proper management of donations and respect for donors' wishes are among the ongoing objectives of Gustave Roussy's fundraising and legacy programme. Donations to Gustave Roussy and its Foundation directly fund innovation in research and care. Gustave Roussy and its Foundation have held 'Don en Confiance' (Giving with Confidence) certification since 2009. Don en Confiance is a certification and monitoring body for associations and foundations that appeal to public generosity.

Don en Confiance accreditation certifies the transparency of fundraising procedures and the proper management of the donations received. **This certification also recognises the exemplary rigour with which Gustave Roussy and its Foundation raise funds: fundraising costs and operating expenses (including HR costs) account for just 14% of private funds raised, one of the lowest ratios in the charitable sector for cancer research.**

FOLLOW US ON SOCIAL MEDIA

GUSTAVE ROUSSY
CANCER CAMPUS GRAND PARIS

Design and production: women-and-men.com